RC18 160 mg plus standard therapy

BIOLOGICAL2 trials

Sponsors

RemeGen Co., Ltd.

Conditions

Systemic Lupus Erythematosus

Phase 2

Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

CompletedNCT02885610

RemeGen Co., Ltd.Systemic Lupus Erythematosus

Start: 2015-12-31End: 2019-07-09Updated: 2020-03-04

Phase 3

Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

CompletedNCT04082416

RemeGen Co., Ltd.Systemic Lupus Erythematosus

Start: 2019-10-16End: 2022-06-30Updated: 2023-05-11

Related Papers

A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.

2025-10-013 citations

Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases2023-12-21107 citations